What it's for (Indications)
- Tacrolimus topical, exemplified by brand names like Eczemus, is precisely indicated for the short-term and intermittent long-term treatment of moderate to severe atopic dermatitis (eczema) in non-immunocompromised adults and pediatric patients aged 2 years and older.
- This medication is typically reserved as a second-line therapeutic option for individuals who have not responded adequately to, or are intolerant of, conventional first-line therapies, particularly topical corticosteroids.
- Its primary utility lies in managing the inflammatory symptoms associated with acute exacerbations of atopic dermatitis, effectively addressing pruritus, erythema, and lichenification.
- The clinical decision to initiate tacrolimus topical therapy should always consider the patient's individual circumstances, including the severity and extent of the disease, as well as their previous treatment history and overall health status.
- The overarching goal of this treatment is to control active disease symptoms, reduce the frequency and severity of future flares, and ultimately enhance the patient's quality of life, aligning with established dermatological treatment protocols.
- It is not indicated for prophylactic use in individuals without a history of atopic dermatitis or as a first-line agent when milder treatments suffice.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | Specific dosage guidelines for topical tacrolimus ointment (e.g., concentration, frequency, duration of application) are not provided in the supplied data. For precise application instructions, please refer to the product's official prescribing information. The provided FDA dosage information pertains to systemic (oral/IV) tacrolimus for organ transplant and is not applicable to topical use. |
Safety & Warnings
Common Side Effects
- Common local side effects include burning, itching, redness, sensitivity, and tingling at the application site.
- Other reported local effects include increased risk of inflamed hair follicles (folliculitis), acne, and herpes simplex reactivation.
- Alcohol intolerance has also been reported.
- Serious adverse reactions, primarily associated with oral or intravenous tacrolimus but warranting consideration due to potential systemic absorption, include an increased risk of Lymphoma and Other Malignancies, Serious Infections, New Onset Diabetes, Nephrotoxicity, Neurotoxicity, Hyperkalemia, Hypertension, Anaphylactic Reactions, Myocardial Hypertrophy, Pure Red Cell Aplasia, and Thrombotic Microangiopathy.
Serious Warnings
- Black Box Warning: WARNING: MALIGNANCIES AND SERIOUS INFECTIONS. Tacrolimus, as an immunosuppressant, carries an increased risk for developing serious infections and malignancies, including lymphoma and skin cancer. This risk, most prominently associated with systemic use, should be considered when prescribing any tacrolimus formulation due to its mechanism of action. Serious infections and malignancies can lead to hospitalization or death.
- Caution is advised in patients with liver failure and generalized erythroderma (intense and widespread skin reddening).
- Patients should minimize exposure to UV light (including sunlight and tanning beds) due to potential for increased skin cancer risk.
- Any pre-existing infections should be treated before initiating therapy.
- Patients should be monitored for enlarged lymph nodes.
- The ointment should be avoided near eyes and mucous membranes.
- Pregnancy and lactation require physician consultation, and use should generally be avoided if possible.
- While primarily associated with systemic use, due to its immunosuppressive mechanism, there is an increased risk of serious infections and malignancies.
- Therapeutic drug monitoring, as well as dosage adjustments based on hepatic/renal function and ethnicity, are typically recommended for systemic tacrolimus and may be considered in cases of significant topical absorption, although less commonly applied to topical preparations.
- Avoid grapefruit or grapefruit juice when using systemic tacrolimus.
How it Works (Mechanism of Action)
Tacrolimus binds to the intracellular protein FKBP-12, forming a complex that inhibits the phosphatase activity of calcineurin. This inhibition prevents the dephosphorylation and translocation of various factors, such as nuclear factor of activated T-cells (NF-AT) and nuclear factor kappa-light-chain enhancer of activated B-cells (NF-κB). Tacrolimus inhibits the expression and/or production of several cytokines (including IL-1 beta, IL-2, IL-3, IL-4, IL-5, IL-6, IL-8, IL-10, gamma interferon, TNF-alpha, and GM-CSF), inhibits IL-2 receptor expression, induces apoptosis, and promotes the production of transforming growth factor beta. The net result is the inhibition of T-lymphocyte activation and overall immunosuppressive activity.